MedTrace Logo

Prevalence, Clinical Features, and Prognosis of Coronary Artery Embolism With Concomitant Atrial Fibrillation

NCT06845956 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5163

Last updated 2025-02-25

No results posted yet for this study

Summary

The goal of this observational study is to learn about the Prevalence, Clinical Features, and Prognosis of Coronary Artery Embolism With Concomitant Atrial Fibrillation. The main question it aims to answer is:

What is the proportion of coronary artery embolism with concomitant atrial fibrillation among all myocardial infarctions and myocardial infarctions with concomitant atrial fibrillation? What are the clinical characteristics of coronary artery embolism with concomitant atrial fibrillation? What is the prognosis of coronary artery embolism with concomitant atrial fibrillation? All participants will receive routine diagnosis and treatment, and baseline demographic data, clinical examination laboratory results, and follow-up data will be collected for analysis.

Conditions

  • Coronary Artery Embolism
  • Acute Myocardial Infarction Type 2

Interventions

OTHER

Is it coronary artery embolism

This observational study categorizes patients with acute myocardial infarction (AMI) into three distinct groups based on their clinical characteristics: 1. Group 1: Patients with atrial fibrillation (AF) and coronary artery embolism (CAE). 2. Group 2: Patients with AF but non-coronary artery embolism myocardial infarction (non-CAE MI). 3. Group 3: Patients without AF and non-coronary artery embolism myocardial infarction (non-CAE MI without AF). A key innovation of this study compared to previous research is its expanded eligibility criteria for AMI patients. Earlier studies typically focused exclusively on ST-segment elevation myocardial infarction (STEMI). In contrast, this investigation encompasses a broader spectrum of acute myocardial infarction, including both STEMI and non-ST-segment elevation myocardial infarction (NSTEMI). This comprehensive approach enhances the generalizability and applicability of the findings by capturing a wider range of clinical scenarios.

Sponsors & Collaborators

  • First Affiliated Hospital of Ningbo University

    lead NETWORK

Principal Investigators

  • CUI H bin, Doctor · Key research and development project of Zhejiang Province,Ningbo Clinical Research Center for Cardiovascular Disease

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06845956 on ClinicalTrials.gov